On December 2, 2023, the TTM Capital 2023 "Miracle" Investment Summit was successfully held in Shanghai. This investment summit, themed "Gathering Talents to Benefit the World, Creating Miracles," is the first annual conference for partners and collaborators since the establishment of TTM Capital.

More than 140 guests from the industry took the time to attend the event, including over 40 leading industry experts, nearly 30 esteemed investors, and more than 70 industry partners. TTM Capital discussed the current investment landscape and trends in the medical ecosystem with colleagues, while attendees freely shared their thoughts, gathering to explore changes in the landscape and discuss industry turning points.

Leading the way, distinguished guests celebrate the industry's grand event

This investment summit specially invited Gang Pei, Academician of the Chinese Academy of Sciences, Academician of the Academy of Sciences for the Developing World, and Academician of the German National Academy of Sciences; Qiang Wu, Member of the Standing Committee of the Pudong New District Committee and Deputy District Mayor, and Deputy Director of the China (Shanghai) Pilot Free Trade Zone Management Committee; and Fei Yuan, Member of the Standing Committee of the Hefei Municipal Committee and Deputy Mayor, to deliver opening speeches for TTM Capital.

Deputy District Chief Qiang Wu

Deputy District Mayor Qiang Wu delivered the opening speech for this meeting, highly recognizing TTM Capital's contributions to establishing ecological services and building the ecosystem in Pudong New District. Deputy District Mayor Qiang Wu introduced the development of Shanghai's medical and health industry and a series of advantages of Pudong New District including the introduction of medical policies, and sincerely invited the entrepreneurial companies and investment institutions present to jointly build a medical and healthcare life circle.

Academician Gang Pei

Academician Gang Pei then delivered a speech. The three core elements of China's biopharmaceutical industry at present are government, capital, and talent. Academician Gang Pei compared the differences between China and the United States in biopharmaceutical development based on these three core elements, leading to the discussion of the challenges faced by China's biopharmaceutical sector and highlighting the significant role of innovation in addressing these challenges. Academician Gang Pei also affirmed TTM Capital's strategies, positioning, layout, and approach in the biopharmaceutical field, and offered sincere wishes for the company's future development.

Fei Yuan, Member of the Standing Committee of the Hefei Municipal Party Committee and Vice Mayor

The development of the industry and the advancement of enterprises are inseparable from the guidance and support of policies. With the strong support of the guiding funds from both the municipal and municipal governments of Hefei, TTM Capital has made smooth progress. At this investment summit, In his speech, Vice Mayor Fei Yuan introduced the development of the biopharmaceutical industry in Hefei, mentioned the emphasis on the biopharmaceutical industry, and sincerely welcomed experts, scholars, entrepreneurs, and investors to Hefei, deepen their engagement in Hefei, and contribute to the construction of Hefei's pharmaceutical industry.

Be devout with original aspiration and counter cyclical develop to create a new chapter

LILY ZHANG, Founder/Managing Partner of TTM Capital

Lily, the founder and managing partner of TTM Capital, introduced the development history and future positioning of TTM Capital to the guests on site with the theme " counter cyclical develop to create a new chapter."

In the past decade of China's healthcare development, TTM Capital has always kept in mind its aspirations of "starting from zero, starting from the heart," and counter cyclical develop when the market turned sharply.

TTM Capital continues to pursue a unique approach of focus, professionalism, honing internal skills. During the ongoing market downturn, TTM has more time to conduct due diligence and make decisions on projects, looking for those with greater investment value and finding certainty amid uncertainty.

In the future, TTM Capital will focus on deep alliances with ecological partners for the long term, facing "adversity" together, adhering to the strategy of " Comprehensive linkage, multi-disciplinary sourcing, strategic alliance," promoting the globalization of medical enterprises, and helping companies "go overseas."

Citing classics, focusing on cutting-edge insights from industry leaders

Ruilin Song, Executive President of the China Pharmaceutical Innovation and Research Development Association(PhIRDA)

At the conference, Ruilin Song, Executive President of PhIRDA, shared and discussed the current situation and challenges of pharmaceutical innovation in China under the title "Pharmaceutical Innovation in China under the New Situation".

Ruilin Song pointed out that, independent innovation capabilities is crucial for start up company. He analyzed this from several dimensions, including the healthcare market landscape, research and development, trading situation, and offshore development, to explore a new landscape for China's pharmaceutical innovation and development. He also reflected on and looked forward to the future development of China's pharmaceutical innovation under the new circumstances, emphasizing the need to innovate from the source and seize opportunities for international expansion.

Continuing the depth of Chairman Song's topic, Xi Zhou, Global Managing Partner of McKinsey, delivered a keynote speech on "The Chinese Innovative Drug Market - Reshaping the Path of Value Creation."

Gather ideas and explore unique perspectives of the entire industry chain

Funding, as the source of power for various industries, has become a focal point of attention for the entire industrial chain. The summit specially invited various industry parties to gather together to explore the real needs and pain points of industry development from multiple perspectives.

"New situation, new pattern, new vision" roundtable dialogue

During the meeting, LILY ZHANG hosted a roundtable dialogue on "New Situation, New Pattern, New Vision." Four guests, including Haoyu Xu, Chairman of Yangtze River Pharmaceutical Group, Zelin Sheng, Chairman of Zelgen Biopharmaceuticals, Hong Shen, Head of Roche China Innovation Center, and Yanan Xu, Head of Global Innovation Collaboration Department for Takeda Pharmaceuticals in China, discussed and shared insights on the trends in the healthcare industry.

Chairman Haoyu Xu emphasized that the pharmaceutical industry, innovative enterprises, capital, and government can only develop towards a better future in a state of symbiotic collaboration. Other guests shared how to maintain their pace during the capital inflow trend, how to cooperate with the domestic medical ecosystem, and shared insights on globalization for Chinese companies.

"Building a Strong Innovation Ecosystem in the Capital Winter" Roundtable Dialogue

Jinsong Wang, Chairman of Habour Biomed, Lei Jin, General Manager of GeneScience Pharmaceutical, Weikang Tao, General Manager of Global Innovative Drug R&D at Qilu Pharmaceutical, Feng Ren, CSO of Insilico Medcine, and Dan Liu, Senior Partner at CDH Investment shared their insights on "the current state of the industry in the cold winter", "where the breakthrough lies," and "how to form innovative cooperation models." The guests believe that the current capital winter provides companies with a time for calm reflection, and future cooperation opportunities among local enterprises will gradually emerge.

Roundtable Dialogue on the Global Development Strategy under the New Situation

Jiguo Zhang, CEO of ChenPartner, Datao Liu, Chairman of Mabwell, Guang Yang, General Manager of China Grand Enterprises Development Headquarters, Wang Wei, Chairman of Winhealth Pharma, Shun Luo, Chairman of Thousand Oak Biologics, and Kun Yang, Partner of Gaorong Ventures, discussed issues such as "the opportunities and challenges faced by Chinese enterprises going abroad and the emergence of new models in the future." The guests believe that the overseas market demand for domestic enterprises is very large, but opportunities and challenges coexist, and hope that domestic enterprises can quickly enter the global market.

Join hands for mutual benefit and create miracles together

Dr. Qing Dong, the chief scientist and founder of Xinthera, a substantial project of TTM Capital, reviewed the process of TTM Capital's strong empowerment and assistance in project mergers and acquisitions, and praised TTM Capital as the closest partner.

Wanjin Hong, an academician of The Agency for Science, Technology and Research (A*STAR) and a recipient of President’s Science & Technology Awards in Singapore, expressed his greetings and congratulations for the TTM Capital Summit, praising TTM Capital for wholeheartedly helping the development of society and entrepreneurial projects, and supporting bilateral cooperation between China and Singapore.

In the current unprecedented major changes of the century, the investment market and the healthcare sector are full of uncertainties. In this reshuffled landscape, those who can grasp the rhythm, innovate and iterate amidst change, accumulate momentum, and prepare for a breakthrough will ultimately clear the fog and find direction. Investment institutions should open up new patterns, deploy new perspectives, and find new angles for healthcare investment, analyzing from multiple dimensions such as investment logic, cognitive barriers, and exit channels to cope with the intricate landscape.

TTM Capital, as a rising star in the investment industry, relies on its strong ability to integrate resources, unique insights, and keen vision, adhering to the value orientation and philosophy of "gathering talents to benefit the world, working hand in hand for mutual success, sailing together to overcome challenges, and creating miracles," embracing partners to achieve win-win outcomes!

About XinThera Pharmaceuticals, Inc